Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Stratton

Showing results (101-110 of 121) with videos related to

Pageof 13
Sort By:
Cancer Immunology, Immunotherapy : CII|March 17, 2016
Human papillomavirus type 16 viral load is decreased following a therapeutic vaccinationHannah N Coleman, William W Greenfield, Shawna L Stratton, et al.
The Journal of Steroid Biochemistry and Molecular Biology|November 21, 2017
Transition from androgenic to neurosteroidal action of 5α-androstane-3α, 17β-diol through the type A γ-aminobutyric acid receptor in prostate cancer progressionDing Xia, Doan V Lai, Weijuan Wu, et al.
JACC. Advances|November 22, 2025
Enhancing Prediction of Cancer Therapy-Related Cardiomyopathy From Surveillance Echocardiograms: A Children's Oncology Group StudyKasey J Leger, Kayla L Stratton, Ritu Sachdeva, et al.
The Lancet. Oncology|February 19, 2020
Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor StudyEugene Suh, Kayla L Stratton, Wendy M Leisenring, et al.
Journal of the National Cancer Institute|June 12, 2026
Modeling long-term mortality and morbidity in pediatric Hodgkin lymphoma survivors after reduced radiotherapy exposureJenna R Rogers, Zachary J Ward, Kayla L Stratton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood CancerElizabeth A M Feijen, Wendy M Leisenring, Kayla L Stratton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2021
Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor StudyKevin C Oeffinger, Kayla L Stratton, Melissa M Hudson, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 13, 2024
Adverse Childhood Experiences, Resilience, and Cardiovascular Disease in Adult Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor StudyLindsay F Schwartz, Kayla L Stratton, Wendy M Leisenring, et al.
JAMA Oncology|February 1, 2019
Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset CardiotoxicityElizabeth A M Feijen, Wendy M Leisenring, Kayla L Stratton, et al.
Journal of Medicinal Chemistry|December 19, 1998
Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308)N Murugesan, Z Gu, P D Stein, et al.
Pageof 13

Showing results (101-110 of 121) with videos related to

Sort By:
Pageof 13
Cancer Immunology, Immunotherapy : CII|March 17, 2016
Human papillomavirus type 16 viral load is decreased following a therapeutic vaccinationHannah N Coleman, William W Greenfield, Shawna L Stratton, et al.
The Journal of Steroid Biochemistry and Molecular Biology|November 21, 2017
Transition from androgenic to neurosteroidal action of 5α-androstane-3α, 17β-diol through the type A γ-aminobutyric acid receptor in prostate cancer progressionDing Xia, Doan V Lai, Weijuan Wu, et al.
JACC. Advances|November 22, 2025
Enhancing Prediction of Cancer Therapy-Related Cardiomyopathy From Surveillance Echocardiograms: A Children's Oncology Group StudyKasey J Leger, Kayla L Stratton, Ritu Sachdeva, et al.
The Lancet. Oncology|February 19, 2020
Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor StudyEugene Suh, Kayla L Stratton, Wendy M Leisenring, et al.
Journal of the National Cancer Institute|June 12, 2026
Modeling long-term mortality and morbidity in pediatric Hodgkin lymphoma survivors after reduced radiotherapy exposureJenna R Rogers, Zachary J Ward, Kayla L Stratton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood CancerElizabeth A M Feijen, Wendy M Leisenring, Kayla L Stratton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2021
Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor StudyKevin C Oeffinger, Kayla L Stratton, Melissa M Hudson, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 13, 2024
Adverse Childhood Experiences, Resilience, and Cardiovascular Disease in Adult Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor StudyLindsay F Schwartz, Kayla L Stratton, Wendy M Leisenring, et al.
JAMA Oncology|February 1, 2019
Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset CardiotoxicityElizabeth A M Feijen, Wendy M Leisenring, Kayla L Stratton, et al.
Journal of Medicinal Chemistry|December 19, 1998
Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308)N Murugesan, Z Gu, P D Stein, et al.
Pageof 13